Nanograb
ActiveDeliver genes to any cell with AI
About
Nanograb is a computational drug discovery company that uses AI to create novel targeted non-viral gene therapy vectors. Our platform designs unique combinations of small peptide binders attached to nanoparticles to safely deliver genetic medicines to specific cells and tissues in the body at scale.
Founders · 3
Co-founder and CEO of Nanograb. PhD in Computational Biophysics from Imperial College London. Experienced in molecular simulations and building software for scientists. First software hire at Fabricnano
Co-founder of Nanograb. M.Eng Biomaterials and Tissue Engineering at Imperial College London. Biomedical engineering experience developing biosensors using aptamers, and a drug delivery device for hypertension management.
Cofounder and in silico lead at Nanograb; Imperial College PhD (dropout); Fascinated by all things compute and physics... all in the name of figuring out real life things! Otherwise, I love singing and music in general. Fun fact: I was in an a cappella group for 5 years :)
Launch
We use AI to generate the best combination of binders to treat different diseases
Nanograb develops AI-driven multivalent binders to target drugs to specific body regions, reducing off-target effects and enabling new therapeutic targeting. The launch presents a platform that generates optimized binder combinations with in vitro and in vivo proof of concept and seeks biopharma partnerships and scientific advisory input.
From the original launch (Jul 2023) — may be outdated.
Related startups
Unleashing the potential of DNA and RNA based therapies using AI
We use AI to design antibodies for intractable diseases
